VICP Registry Case Source Bundle
Canonical URL: https://vicp-registry.org/case/USCOURTS-cofc-1_20-vv-00732
Package ID: USCOURTS-cofc-1_20-vv-00732
Petitioner: Jackilyn Davis
Filed: 2020-06-19
Decided: 2021-11-23
Vaccine: Tdap
Vaccination date: 2019-04-20
Condition: Guillain- Barre Syndrome (GBS) and acute inflammatory demyelinating polyneuropathy (AIDP)
Outcome: compensated
Award amount USD: 100000

AI-assisted case summary:
Jackilyn Davis filed a petition for compensation under the National Vaccine Injury Program on June 19, 2020. Ms. Davis alleged that she suffered from Guillain-Barre Syndrome (GBS) and acute inflammatory demyelinating polyneuropathy (AIDP) as a result of receiving a Tdap vaccine on April 20, 2019. The respondent, the Secretary of Health and Human Services, denied that the Tdap vaccine caused Ms. Davis's GBS or any other injury. The parties, maintaining their respective positions, reached a stipulation to settle the case. Under the terms of the stipulation, the respondent agreed to pay Ms. Davis a lump sum of $100,000.00, payable by check to the petitioner. This amount is intended to compensate for all damages available under the Vaccine Act. Special Master Thomas L. Gowen issued a decision on the stipulation on November 23, 2021, and judgment was entered in accordance with the stipulation. The public decision does not describe the specific onset of symptoms, medical tests, treatments, or expert witnesses. Petitioner was represented by Emily Ashe of Anapol Weiss, and respondent was represented by Terrence Mangan of the U.S. Department of Justice.

Theory of causation field:
Petitioner Jackilyn Davis alleged that a Tdap vaccine administered on April 20, 2019, caused her to suffer from Guillain-Barre Syndrome (GBS) and acute inflammatory demyelinating polyneuropathy (AIDP). The respondent denied causation. The parties reached a stipulation for settlement, agreeing to an award of $100,000.00. The public decision does not detail the specific theory of causation, medical experts, or the mechanism of injury. The decision was issued by Special Master Thomas L. Gowen on November 23, 2021. Petitioner's counsel was Emily Ashe, and respondent's counsel was Terrence Mangan.

Public staged source text:

================================================================================
DOCUMENT 1: USCOURTS-cofc-1_20-vv-00732-0
Date issued/filed: 2021-12-14
Pages: 2
Docket text: PUBLIC DECISION (Originally filed: 11/23/2021) regarding 35 DECISION for Stipulation. Signed by Special Master Thomas L. Gowen. (slw) Service on parties made.
--------------------------------------------------------------------------------
Case 1:20-vv-00732-UNJ Document 36 Filed 12/14/21 Page 1 of 2
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
Filed: November 23, 2021
* * * * * * * * * * * * * Unpublished
JACKILYN DAVIS, *
Petitioner, * No. 20-732V
*
v. * Special Master Gowen
*
SECRETARY OF HEALTH * Decision on Stipulation;
AND HUMAN SERVICES, * Tdap; Guillain- Barre Syndrome
* (“GBS”).
Respondent. *
* * * * * * * * * * * * *
Emily Ashe, Anapol Weiss, Philadelphia, PA, for petitioner.
Terrence Mangan, U.S. Department of Justice, Washington, D.C., for respondent.
DECISION ON STIPULATION1
On June 19, 2020, Jackilyn Davis (“petitioner”), filed a petition for compensation under
the National Vaccine Injury Program.2 Petition (ECF No. 1). Petitioner alleges that as a result
of the Tdap vaccine on April 20, 2019, she suffered from Guillain- Barre Syndrome (“GBS”) and
acute inflammatory demyelinating polyneuropathy (“AIDP”). Id. at Preamble.
On November 23, 2021, respondent filed a stipulation providing that a decision should be
entered awarding compensation to petitioner. Stipulation (ECF No. 34). Respondent denies that
the Tdap vaccine is the cause of petitioner’s GBS or any other injury or her current condition.
Id. at ¶ 6. Nevertheless, maintaining their respective positions, the parties now agree that the
issues between them shall be settled and that a decision should be entered awarding the
1 Pursuant to the E-Government Act of 2002, see 44 U.S.C. § 3501 note (2012), because this opinion contains a
reasoned explanation for the action in this case, I am required to post it on the website of the United States Court of
Federal Claims. The court’s website is at http://www.uscfc.uscourts.gov/aggregator/sources/7. This means the
opinion will be available to anyone with access to the Internet. Before the opinion is posted on the court’s
website, each party has 14 days to file a motion requesting redaction “of any information furnished by that party:
(1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that
includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of
privacy.” Vaccine Rule 18(b). “An objecting party must provide the court with a proposed redacted version of the
decision.” Id. If neither party files a motion for redaction within 14 days, the opinion will be posted on the
court’s website without any changes. Id.
2 The National Vaccine Injury Compensation Program is set forth in Part 2 of the National Childhood Vaccine
Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as amended, 42 U.S.C. §§ 300aa-1 to -34 (2012)
(Vaccine Act or the Act). All citations in this decision to individual sections of the Vaccine Act are to 42 U.S.C.A. §
300aa.

Case 1:20-vv-00732-UNJ Document 36 Filed 12/14/21 Page 2 of 2
compensation to the petitioner according to the terms of the stipulation attached hereto as
Appendix A. Id. at ¶ 7.
The stipulation provides:
a) A lump sum of $100,000.00 in the form of a check payable to petitioner.
These amounts represent compensation for all damages that would be available under 42 U.S.C.
§300aa-15(a).
Accordingly, the Clerk of the Court SHALL ENTER JUDGMENT in accordance with
the terms of the stipulation and this decision.3
IT IS SO ORDERED.
s/Thomas L. Gowen
Thomas L. Gowen
Special Master
3 Entry of judgment is expedited by each party’s filing notice renouncing the right to seek review. Vaccine Rule
11(a).
2